IMPALA study (indication colorectal cancer)

IMPALA is a randomized, international, multicenter, open-label phase III trial. The study aims to prove that a switch maintenance therapy with an active immunotherapy leads to an increased overall survival of patients who have achieved a response during their first line treatment of metastatic colorectal cancer. The primary endpoint is overall survival and secondary study endpoints include progression-free survival, toxicity and safety, and Quality of Life (QoL).

Recruitment of the IMPALA study started in September 2014 and so far 540 patients are enrolled in 8 European countries. The Patient recruitment goal has been achieved in 2017.

Leading medical associations will collaborate: Arbeitsgemeinschaft Internistische Onkologie (AIO) in Germany, Grupo Españiol de Tratamiento de Tumores Digestivos (TTD) in Spain and Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR) in France.

For more information on the trials IMPACT and IMPALA please visit www.clinicaltrials.gov.